Boston - based company has closed an $ 80 million series A funding round , led by Sequoia Capital China and Serica Partners . Molecular diagnostic specialist NuProbe has developed a highly sensitive , non - invasive blood test enabling the early detection of cancer and other diseases . The latest technology will be used to continue clinical trials and for work on developing a commercial product , as well as to expand staffing at NuProbe 's US and UK offices . Private US biotechnology firms received $ 1.4bn of Chinese investment during Q1 2018 , according to Forbes .
Boston-based NuProbe has closed an $11m series A funding round, led by Sequoia Capital China and Serica Partners. Molecular diagnostic specialist NuProbe has developed a highly sensitive, non-invasive blood test enabling the early detection of cancer and other diseases. The latest investment will be used to continue clinical trials and for work on developing a commercial product, as well as to expand staffing at NuProbe's US and China offices. Private US biotechnology firms received $1.4bn of Chinese investment during Q1 2018, according to PitchBook.